Fucosidosis - Type I
Etiology and Pathogenesis [1,2]
Enzyme deficiency results in accumulation of glycosphingolipids (primarily H-antigen) in the central nervous system and peripheral tissues. Key Symptom Images
 |
 |
 |
 |
 |
 |
| Hepatosplenomegaly |
 |
Macroglossia |
 |
 |
Image Credits: Hepatosplenomegaly courtesy of The National MPS Society, Inc.
Clinical Description and Progression/Prognosis [1,2]
Progressive neurologic deterioration begins after the 1st year of life, accompanied by spasticity, tremors, and mild skeletal changes. Lungs, heart, liver, pancreas, kidneys, cornea, skin, mucous-secreting glands, lymphocytes, peripheral nerves, and spleen are affected. Somatic features are similar to those in MPS.
Type I (the infantile form) makes up 60% of all fucosidosis cases. It has an early and rapid course, with death occurring around 5 years of age. Inheritance pattern: autosomal recessive Incidence: unknown Diagnosis: Clinical symptoms Conditions with similar presentations: MPS, Fabry (angiokerotomas) [3] Management: no disease-specific treatment available Other medical care: symptom management
 Psychomotor retardation  Beginning to fall off milestones around end of 1st year of life  Weakness and hypotonia initially, with eventual spastic quadriplegia  Seizures  Progressive mental retardation
 Hepatomegaly / hepatosplenomegaly  Macroglossia  Progressive impairment of gallbladder function
 Brachycephalic skull  Frontal bossing  Coarse facial features  Growth retardation  Lumbar kyphosis  Joint contractures
Back to categories  Chronic recurrent lung infections
 Cardiomegaly
 Tortuous conjunctival vessels  Slight corneal clouding  Pigmentary retinopathy
 Thick skin  Hyperhydrosis
Back to categories

1. Hauser SL, Longo DL, eds. Harrison’s Principles of Internal Medicine. 14th ed. New York: McGraw-Hill; 1998; p. 2175.
2. Hensyl W, ed. Stedman’s Medical Dictionary. 25th ed. Baltimore: Williams & Wilkins; 1990; p. 622.
3. OMIM. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=230000. Accessed August 2004. |